Where clinical judgement meets valuation rigour.
I'm a practicing physician who spent three years building financial models and analysing clinical trial data in pharmaceutical equity research, and before that, developing growth strategy at a leading consultancy.
I help biotech and medtech companies turn clinical evidence into investor-ready numbers and defensible commercial strategy.
Practicing physician — Currently in clinical practice (MBBS from Imperial College London)
Equity Research — Pharmaceutical & biotech coverage
Senior Associate — Strategy consulting
Three kinds of teams tend to reach out
Early-stage biotech
Building a valuation model or investor deck ahead of a raise, and want the clinical evidence and the numbers to hold together under scrutiny.
Medtech & device teams
Sizing a market, mapping the competitive and reimbursement landscape, and need a clinician's read on how the evidence will actually land with prescribers and payers.
Small teams without in-house depth
Have the science but not the financial or strategic bandwidth in-house, and want an expert they can bring in as needed rather than hire full-time.
Three ways to work together
Each is scoped up front, so you know what you're getting and what it costs before we start.
Valuation & financial modelling
An investor-ready valuation model built on the actual clinical evidence — not a generic template.
Deliverables
- Patient disease & peak sales modelling
- Catalyst-adjusted DCF or comparables analysis
- Model built to withstand investor diligence questions
Strategic & commercial advisory
Market landscape, competitive positioning, and reimbursement pathway assessment, grounded in clinical reality.
Deliverables
- Competitive & catalyst landscape review
- Reimbursement & access pathway assessment
- Clinician's read on trial design and evidence gaps
Fractional advisory
Ongoing, light-touch input for teams that want an expert on call rather than a one-off project.
Deliverables
- Monthly working sessions
- Ad hoc review of decks, models, or evidence summaries
- Direct line for time-sensitive questions
How a project usually runs
A short call to define the question and the deliverable.
A price and timeline before any work begins.
Model or assessment built with check-ins along the way.
Working session to walk through the output together.
Clinical practice, equity research, and strategy — not in sequence, in parallel
MBBS from Imperial College London, currently a practicing physician.
Three years in pharmaceutical equity research, covering large-cap pharma and biotech, building disease models and assessing clinical trial catalysts.
Prior to that, Senior Associate in strategy consulting, including buy-side due diligence and long-term growth strategy for healthcare organisations.
Bring the clinical evidence.
I'll bring the model.
Tell me a little about the asset or the question, and I'll get back to you with scope and a fixed quote.
Disclaimer: This work supports biotech and medtech companies with valuation modelling and strategic advisory on their own business. It is not investment advice and is not directed at investors seeking recommendations on specific securities.
© Dr. Folashade Oyewole